DR5 Cancer Research Results

DR5, Death receptor 5: Click to Expand ⟱
Source:
Type:
A protein reported to play an important role in sensitizing cancer cells to apoptosis. Death Receptor 5 (DR5), also known as TRAIL receptor 2, is a member of the tumor necrosis factor (TNF) receptor superfamily. It plays a crucial role in the apoptosis (programmed cell death) pathway, particularly in the context of cancer.
DR5 is often overexpressed in various types of tumors, including breast, colon, and lung cancers. This overexpression can make cancer cells more susceptible to TRAIL-induced apoptosis.
Scientific Papers found: Click to Expand⟱
4957- PEITC,    Phenethyl Isothiocyanate (PEITC) from Cruciferous Vegetables Targets Human Cancer Stem-Like Cells
- vitro+vivo, Cerv, HeLa
CSCs↓, ALDH↓, CD44↓, CD24↓, cl‑PARP↑, DR4↑, DR5↑,
4960- PEITC,    Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells
- in-vivo, Cerv, HeLa
CD44↓, CD24↓, CSCs↓, cl‑PARP↑, DR4↑, DR5↑, TumCP↓,
4918- PEITC,    Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights
- Review, Var, NA
Apoptosis↑, TumCP↓, angioG↓, TumMeta↓, NF-kB↓, Akt↓, MAPK↓, *BioAv↓, ROS↑, lipid-P↑, AIF↑, Cyt‑c↑, DR4↑, DR5↑, TumCCA↑, JAK↓, STAT3↓, MMP2↓, MMP9↓, PKCδ↓, Hif1a↓, JNK↓, Mcl-1↓, COX2↓, MMP↓, Casp3↑, ChemoSen↑, *BioAv↓, Half-Life↓,
5159- PLB,    Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression
- in-vitro, AML, K562
tumCV↓, Apoptosis↑, ROS↑, eff↓, DR4↑, DR5↑, TRAIL↑,
4967- PSO,    Psoralidin's Anti-Cancer Mechanisms: A Technical Guide
- Review, Var, NA
NF-kB↓, PI3K↓, Akt↓, ITGB1↓, FAK↓, BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, DR5↑, TumCCA↑, TumAuto↑, TumMeta↓,
64- QC,    Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
- in-vitro, Colon, HT-29 - in-vitro, Colon, SW-620 - in-vitro, Colon, Caco-2
Cyt‑c↑, BAX↑, Casp3↑, DR4↑, DR5↑,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- Review, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓, TumCCA↑, ROS↑, miR-21↓, TumCP↓, selectivity↑, PDGF↓, EGF↓, TNF-α↓, VEGFR2/KDR/Flk1↓, mTOR↓, cMyc↓, MMPs↓, GRP78/BiP↑, CHOP/DDIT3↑,
69- QC,    Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
TRAIL↑, Casp3↑, Casp9↑, Casp8↑, DR5↑,
47- QC,    Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells
- in-vitro, NSCLC, H460 - in-vitro, NSCLC, A549
TRAIL↑, DR5↑, survivin↓,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1/CCND1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
914- QC,    Quercetin and Cancer Chemoprevention
- Review, NA, NA
GSH↓, ROS↑, TumCCA↑, Ca+2↑, MMP↓, Casp3↑, Casp8↑, Casp9↑, β-catenin/ZEB1↓, AMPKα↑, ASK1↑, p38↑, TRAIL↑, DR5↑, cFLIP↓, Apoptosis↑,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP/DDIT3↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2/KDR/Flk1↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
3098- RES,    Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers
- Review, Var, NA
NOTCH2↓, Wnt↓, β-catenin/ZEB1↓, p‑SMAD2↓, p‑SMAD3↓, PTCH1↓, Smo↓, Gli1↓, E-cadherin↑, NOTCH⇅, TAC?, NKG2D↑, DR4↑, survivin↓, DR5↑, BAX↑, p27↑, cycD1/CCND1↓, Bcl-2↓, STAT3↓, STAT5↓, JAK↓, DNAdam↑, γH2AX↑,
3061- RES,    The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
- Review, Var, NA
AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27↑, cycD1/CCND1↓, SIRT1↑, NF-kB↓, ATF3↑,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1465- SFN,    TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells
- NA, Bladder, NA
eff↑, Apoptosis↑, Casp↑, MMP↓, BID↑, DR5↑, ROS↑, NRF2↑, eff↑, eff↓,
1458- SFN,    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
- Review, Bladder, NA
HDAC↓, eff↓, TumW↓, TumW↓, angioG↓, *toxicity↓, GutMicro↝, AntiCan↑, ROS↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8∅, cl‑PARP↑, TRAIL↑, DR5↑, eff↓, NRF2↑, ER Stress↑, COX2↓, EGFR↓, HER2/EBBR2↓, ChemoSen↑, NF-kB↓, TumCCA?, p‑Akt↓, p‑mTOR↓, p70S6↓, p19↑, P21↑, CD44↓, CSCs↓,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
2196- SK,    Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species
- Review, Var, NA
*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,
1928- TQ,    Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
TumCP↓, DR4↑, DR5↑, Casp8↑, FADD↑, Bcl-2↓, ROS↑, NO↑, MDA↑,
2123- TQ,    Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma
- in-vitro, lymphoma, PEL
Akt↓, ROS↑, BAX↓, MMP↓, Cyt‑c↑, eff↑, Casp9↑, Casp3↑, cl‑PARP↑, DR5↑,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2/KDR/Flk1↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3790- UA,    Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools
*Inflam↓, *antiOx↑, AntiCan↑, *neuroP↑, *hepatoP↑, *cardioP↑, *MMP↑, *ROS↓, *PGC-1α↑, *BDNF↑, *cognitive↑, Bcl-2↓, Cyt‑c↑, DR5↑, Casp9↑, Casp8↑, Casp3↑, TumCCA↑, *BioAv↓, *Dose↝, *Half-Life↓, *Half-Life↓,

Showing Research Papers: 51 to 74 of 74
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 74

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ATF3↑, 1,   GPx4↓, 1,   GSH↓, 2,   GSH↑, 1,   HO-1↑, 2,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 1,   MDA↑, 1,   NRF2↑, 4,   ROS?, 1,   ROS↓, 1,   ROS↑, 11,   ROS⇅, 2,   SOD↑, 1,   TAC?, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   CDC2↓, 1,   CDC25↓, 1,   EGF↓, 2,   FGFR1↓, 1,   MEK↓, 1,   MMP↓, 7,   Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 4,   Glycolysis↓, 1,   LDH↑, 1,   PKM2↓, 1,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

AhR↓, 1,   Akt↓, 8,   Akt↑, 1,   p‑Akt↓, 2,   Apoptosis↑, 7,   ASK1↑, 1,   Bak↑, 2,   BAX↓, 1,   BAX↑, 7,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   Bcl-2↑, 1,   Bcl-xL↓, 2,   BID↓, 1,   BID↑, 1,   BIM↑, 2,   Casp↑, 1,   Casp10↑, 1,   Casp3↓, 1,   Casp3↑, 13,   Casp8↑, 6,   Casp8∅, 1,   pro‑Casp8↑, 1,   Casp9↑, 11,   cFLIP↓, 2,   Cyt‑c↑, 7,   Diablo↑, 1,   DR4↑, 9,   DR5↓, 1,   DR5↑, 23,   FADD↑, 2,   Fas↑, 3,   FasL↑, 2,   iNOS↓, 2,   JNK↓, 1,   JNK↑, 2,   MAPK↓, 3,   MAPK↑, 2,   Mcl-1↓, 4,   Myc↓, 1,   NOXA↑, 1,   p27↑, 4,   p38↑, 3,   survivin↓, 7,   TNFR 1↑, 1,   TRAIL↑, 6,   TRAILR↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,   HER2/EBBR2↓, 2,   p70S6↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-21↓, 1,   miR-21↑, 1,   other↓, 1,   p‑pRB↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   eIF2α↓, 1,   eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 2,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 2,   LC3B-II↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

CYP1B1↑, 1,   DFF45↑, 1,   DNAdam↑, 1,   DNMT1↓, 1,   p16↑, 1,   P53↑, 6,   PARP↓, 1,   PARP↑, 1,   cl‑PARP↑, 5,   PCNA↓, 1,   UHRF1↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 3,   CDK2↓, 2,   CDK2↑, 1,   CDK4↓, 1,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   E2Fs↓, 1,   p19↑, 1,   P21↑, 4,   TumCCA?, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD24↓, 2,   CD44↓, 3,   cMET↓, 1,   CSCs↓, 5,   EMT↓, 3,   ERK↓, 2,   ERK↑, 1,   FGF↓, 1,   FOXM1↓, 1,   FOXO↑, 2,   FOXO3↑, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   HDAC↓, 1,   HDAC1↓, 1,   IGFBP3↑, 1,   mTOR↓, 5,   p‑mTOR↓, 2,   NOTCH↓, 2,   NOTCH⇅, 1,   NOTCH1↓, 1,   NOTCH2↓, 1,   P70S6K↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 8,   p‑PI3K↓, 1,   PTCH1↓, 1,   RAS↓, 1,   Shh↓, 2,   Smo↓, 1,   STAT3↓, 6,   STAT5↓, 1,   TumCG↓, 1,   Wnt↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 2,   AP-1↓, 2,   Ca+2↑, 1,   Ca+2↝, 1,   COL1↓, 1,   COL3A1↓, 1,   DLC1↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 1,   FAK↓, 2,   ITGA5↓, 1,   ITGB1↓, 1,   LEF1↓, 1,   MMP2↓, 4,   MMP7↓, 2,   MMP9↓, 3,   MMPs↓, 3,   N-cadherin↓, 1,   PDGF↓, 2,   PKCδ↓, 1,   RAGE↓, 1,   Slug↓, 2,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 2,   TSP-1↑, 2,   TumCP↓, 5,   TumMeta↓, 2,   Twist↓, 1,   uPA↓, 1,   uPAR↓, 1,   Vim↓, 2,   Zeb1↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   ATF4↑, 1,   EGFR↓, 4,   Hif1a↓, 2,   NO↑, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 3,  

Barriers & Transport(tgid=15) ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 6,   CRP↓, 1,   CXCL1↓, 1,   CXCR4↓, 1,   IFN-γ↓, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↓, 2,   IL12↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 3,   IL8↓, 1,   Inflam↓, 1,   JAK↓, 2,   JAK2↓, 1,   NF-kB↓, 9,   p65↓, 1,   PSA↓, 1,   TLR4↓, 1,   TNF-α↓, 4,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 4,   eff↓, 5,   eff↑, 6,   eff↝, 1,   Half-Life↓, 1,   P450↓, 1,   selectivity↑, 1,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   EGFR↓, 4,   FOXM1↓, 1,   GutMicro↝, 1,   HER2/EBBR2↓, 2,   IL6↓, 3,   LDH↑, 1,   Myc↓, 1,   PSA↓, 1,   RAGE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   NKG2D↑, 1,   TumW↓, 2,  
Total Targets: 251

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 3,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   FASN↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   IL8↓, 1,   Inflam?, 1,   Inflam↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↝, 1,   Dose↝, 1,   Half-Life↓, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 32

Scientific Paper Hit Count for: DR5, Death receptor 5
9 Baicalein
8 Quercetin
6 Fisetin
5 Luteolin
4 Ashwagandha(Withaferin A)
3 chaetocin
3 Garcinol
3 Phenethyl isothiocyanate
3 Sulforaphane (mainly Broccoli)
3 Thymoquinone
2 Apigenin (mainly Parsley)
2 Boswellia (frankincense)
2 Honokiol
2 Resveratrol
1 Allicin (mainly Garlic)
1 Chemotherapy
1 Artemisinin
1 Boron
1 Butyrate
1 Chrysin
1 Curcumin
1 Ellagic acid
1 Eugenol
1 Formononetin
1 Gallic acid
1 Juglone
1 Magnolol
1 Melatonin
1 Niclosamide (Niclocide)
1 Nimbolide
1 Plumbagin
1 Psoralidin
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Ursolic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:88  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page